Australian researchers have identified the coagulation factor II receptor (F2R) as a promising new prognostic biomarker and treatment target for ovarian cancer that may allow physicians to more accurately predict treatment responses and personalize therapies to improve outcomes.

Lead researcher Hugo Albrecht, PhD, from the Centre of Pharmaceutical Innovation at the University of South Australia in Adelaide, said the finding marks “a significant step forward” in the study of ovarian cancer, for which there is an urgent clinical need for effective treatment options and improved diagnostic and prognostic technologies.

“Current biomarkers lack sensitivity and accuracy, leaving clinicians with few tools for early detection or to reliably predict treatment outcomes,” he remarked. “However, we

See Full Page